Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077257 | 0.82 | PIK3CD (0.39) | KMT2AMEN1GAAMAPTRECQL | |
| SCHEMBL4080191 | 0.78 | ALOX5 (0.35) | KMT2AMEN1GAAMAPTRECQL | |
| SCHEMBL4076521 | 0.77 | KMT2A (0.57) | KMT2AMEN1GAAMAPTRECQL | |
| SCHEMBL3973340 | 0.75 | PTGDR2 (0.35) | KMT2AMEN1GAAMAPTRECQL | |
| SCHEMBL27826404 | 0.73 | CNR1 (0.35) | KMT2AMEN1GAAMAPTRECQL | |
| SCHEMBL4086084 | 0.71 | PIK3CD (0.38) | KMT2AMEN1GAAMAPTRECQL | |
| SCHEMBL3971702 | 0.70 | PIK3CD (0.38) | KMT2AMEN1GAAMAPTRECQL | |
| SCHEMBL4494239 | 0.68 | IDH1 (0.35) | KMT2AMEN1GAAMAPTRECQL | |
| SCHEMBL4073483 | 0.61 | PIK3CD (0.46) | KMT2AMEN1GAAMAPTCYP11B2 | |
| SCHEMBL4079104 | 0.59 | IDH1 (0.38) | KMT2AMEN1GAAMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501031-B | Oxazolidone derivatives as PR modulators | WYETH (US) | 2012-02-01 | — | — | CN | claimed |
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | claimed |
| WO-2008021339-A2 | PYRROLIDINE AND RELATED DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | claimed |
| CN-101501031-B | Oxazolidone derivatives as PR modulators | WYETH (US) | 2012-02-01 | — | — | CN | disclosed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| CN-101501031-A | Oxazolidone derivatives as pr modulators | WYETH CORP (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021339-A2 | PYRROLIDINE AND RELATED DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | PRLHR, GNRHR, NPY1R | KMT2A 492/4885MEN1 135/4885GAA 4819/4885 |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | MC2R, NPY1R, PRLHR | KMT2A 667/4885MEN1 699/4885GAA 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.